uploads///syringe __

Analyst Ratings for AMAG Pharmaceuticals and Peers in February

By

Dec. 4 2020, Updated 10:53 a.m. ET

Company overview

AMAG Pharmaceuticals (AMAG) is a biopharmaceutical company with a focus on clinical research and the development of therapeutics. Its products are targeted at maternal and women’s health, anemia management, and supportive care for cancer patients. Its products include Makena and Ferahame for intravenous use, MuGard oral wound rinse, and Intrarosa vaginal inserts for the treatment of dyspareunia.

AMAG also provides services for preserving umbilical cord stem cells and cord tissue units through cord blood registry. It also helps preserve newborn stem cells used in transplant medicine for cancer and blood, immune, and metabolic disorders. It believes its work has valuable potential in the development of regenerative medicine.

In February 2017, the company acquired the rights for the research, development, and commercialization of bremelanotide in North America. Bremelanotide is under development for the treatment of hypoactive sexual desire disorder (or HSDD) in pre-menopausal women.

Article continues below advertisement

Analyst recommendations

Of the 12 analysts covering AMAG Pharmaceuticals in February 2018, three of them have given the stock a “buy” or higher rating, and nine have given it a “hold.” The mean rating for the stock is 2.6 with a target price of $18.36.

Peer ratings

Of the 25 analysts covering Amgen (AMGN) in February 2018, ten of them have given the stock a “buy” or higher rating, and 15 have given it a “hold.” The mean rating for the stock is 2.4 with a target price of $195.29.

Of the 22 analysts covering Merck & Co. (MRK) in February 2018, 13 of them have given the stock a “buy” or higher rating, and nine have given it a “hold.” The mean rating for the stock is 2.1 with a target price of $66.67.

Of the 23 analysts covering Pfizer (PFE) in February 2018, 12 of them have given the stock a “buy” or higher rating, and nine have given it a “hold.” The mean rating for the stock is 2.6 with a target price of $40.25.

In the next part of this series, we’ll take a look at AMAG Pharmaceuticals’ key collaborations.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.